Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O95278: Variant p.Gly240Ser

Laforin
Gene: EPM2A
Feedback?
Variant information Variant position: help 240 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Serine (S) at position 240 (G240S, p.Gly240Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In EPM2; impaired phosphatase activity; does not affect glycogen binding; disrupts the interaction with PPP1R3C. Any additional useful information about the variant.


Sequence information Variant position: help 240 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 331 The length of the canonical sequence.
Location on the sequence: help LYREEGLAYIWMPTPDMSTE G RVQMLPQAVCLLHALLEKGH The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         LYREEGLAYIWMPTPDMSTEGRVQMLPQAVCLLHALLEKGH

                              LYKEEGLVYIWMPTPDMSTEGRVQMLPQAVCLLHALLENGH

Mouse                         LYKEEGLSYIWMPTPDMSTEGRVQMLPQAVCLLHALLENGH

Rat                           LYKEEGLAYIWMPTPDMSTEGRVQMLPQAVCLLHALLENGH
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 331 Laforin
Domain 156 – 323 Tyrosine-protein phosphatase
Binding site 235 – 235
Binding site 241 – 241
Alternative sequence 1 – 243 Missing. In isoform 6.
Alternative sequence 160 – 293 Missing. In isoform 5.
Alternative sequence 200 – 331 Missing. In isoform 4.
Mutagenesis 235 – 235 D -> A. Complete loss of phosphatase activity. Does not affect glycogen binding.
Mutagenesis 236 – 236 M -> A. Complete loss of phosphatase activity. No effect on glycogen binding.
Mutagenesis 250 – 250 C -> S. No effect on homodimerization or carbohydrate binding. Decreased phosphatase activity.
Mutagenesis 251 – 251 L -> A. Impairs protein stability. Strongly reduces phosphatase activity. No effect on glycogen binding.
Helix 238 – 258



Literature citations
Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.
Fernandez-Sanchez M.E.; Criado-Garcia O.; Heath K.E.; Garcia-Fojeda B.; Medrano-Fernandez I.; Gomez-Garre P.; Sanz P.; Serratosa J.M.; Rodriguez de Cordoba S.;
Hum. Mol. Genet. 12:3161-3171(2003)
Cited for: FUNCTION; CATALYTIC ACTIVITY; SELF-INTERACTION; SUBCELLULAR LOCATION; GLYCOGEN-BINDING; INTERACTION WITH PPP1R3C; TISSUE SPECIFICITY; MUTAGENESIS OF ASP-235 AND CYS-266; ACTIVE SITE; CHARACTERIZATION OF VARIANTS EPM2 GLY-32; LEU-84; CYS-108; ILE-194; SER-240; SER-279; LEU-293; ASN-294 AND LEU-301; Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease.
Raththagala M.; Brewer M.K.; Parker M.W.; Sherwood A.R.; Wong B.K.; Hsu S.; Bridges T.M.; Paasch B.C.; Hellman L.M.; Husodo S.; Meekins D.A.; Taylor A.O.; Turner B.D.; Auger K.D.; Dukhande V.V.; Chakravarthy S.; Sanz P.; Woods V.L. Jr.; Li S.; Vander Kooi C.W.; Gentry M.S.;
Mol. Cell 57:261-272(2015)
Cited for: X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-329 IN COMPLEX WITH MALTOHEXAOSE AND PHOSPHATE; CATALYTIC ACTIVITY; FUNCTION; SUBUNIT; MUTAGENESIS OF VAL-8; LYS-87; TRP-99; ILE-126; THR-142; ASP-197; MET-236 AND CYS-266; CHARACTERIZATION OF VARIANTS EPM2 GLY-32; HIS-171; SER-240; ASN-294 AND LEU-301; Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
Gomez-Garre P.; Sanz Y.; Rodriguez de Cordoba S.R.; Serratosa J.M.;
Eur. J. Hum. Genet. 8:946-954(2000)
Cited for: VARIANTS EPM2 LEU-84; SER-240 AND LEU-301;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.